Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
Alefacept is a new anti-psoriatic drug within the group of the so-called biologics. In about
30% of patients alefacept induces a more than 75% improvement of psoriasis after a 12-week
treatment period. The start of anti-psoriatic effect by alefacept is delayed, however
improvement of psoriatic lesions outlasts the end of alefacept treatment.
Narrowband UVB (UVB-311nm) phototherapy is an established anti-psoriatic treatment regimen
with rapid onset of anti-psoriatic efficacy but disease-free intervals after the end of
successful treatment courses may be short.
Therefore, in this half-side (left/right side) comparison study we aim to investigate whether
an additional narrowband UVB treatment accelerates and improves the anti-psoriatic treatment
effects of alefacept.